Vaccine Discovery

As an organization focused on the poxvirus-based vaccine candidate, EuroVacc’s leading candidate is NYVAC developed in collaboration with Sanofi Pasteur. NYVAC is a highly attenuated vaccinia virus strain and has been used as a vector not just for HIV/AIDS vaccines but also for vaccines against other infectious diseases. NYVAC has been tested in multiple clinical trials in humans and has established an excellent safety profile (Gomez, 2008).

EuroVacc is also developing MVA-based vaccine candidate. MVA is another highly attenuated vaccinia virus strain (Gomez, 2008). Preliminary preclinical research has demonstrated that, though both NYVAC and MVA derive from the vaccinia virus, the type of immune responses they induce are very different.